Comparison of Targeted Next-Generation and Sanger Sequencing for the BRCA1 and BRCA2 Mutation Screening

참고문헌 (10)

1. Banerjee S, "Making the best of PARP inhibitors in ovarian cancer", Nat Rev Clin Oncol, 7, pp.508~519 (2010)
2. Secord AA, "Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer", Int J Gynecol Cancer, 23, pp.846~852 (2013)
3. Yazici H, "BRCA1 and BRCA2 mutations in Turkish familial and non‐familial ovarian cancer patients: a high incidence of mutations in non‐familial cases", Hum Mutat, 20, pp.28~34 (2002)
4. Friedman LS, "Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families", Nat Genet, 8, pp.399~404 (1994)
5. Meindl A, "Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population", Int J Cancer, 97, pp.472~480 (2002)
6. Vehmanen P, "Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes", Hum Mol Genet, 6, pp.2309~2315 (1997)
7. Rothberg JM, "An integrated semiconductor device enabling non-optical genome sequencing", Nature, 475, pp.348~352 (2011)
8. Bragg LM, "Shining a light on dark sequencing: characterising errors in Ion Torrent PGM data", PLoS Comput Biol, 9, pp.e1003031~ (2013)
9. Anczuków O, "BRCA2 deep intronic mutation causing activation of a cryptic exon: opening toward a new preventive therapeutic strategy", Clin Cancer Res, 18, pp.4903~4909 (2012)
10. Sikkema-Raddatz B, "Targeted next-generation sequencing can replace Sanger sequencing in clinical diagnostics", Hum Mutat, 34, pp.1035~1042 (2013)

관련 논문AI추천